FDA Roundup: Agency Highlights from July 2024
FDA Approval Marks Epysqli as Second Soliris Biosimilar The FDA approved the Biologics License Application for eculizumab-aagh (Epysqli) as a biosimilar to eculizumab (Soliris). The biosimilar has been approved for the treatment of patients with paroxysmal …